Pain Therapeutics (PTIE) Announces Earnings Results, Beats Estimates By $0.50 EPS

Pain Therapeutics (NASDAQ:PTIE) issued its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.50, MarketWatch Earnings reports.

PTIE traded down $0.05 on Tuesday, reaching $1.12. The company’s stock had a trading volume of 752 shares, compared to its average volume of 5,851,778. The company has a market capitalization of $8.52 million, a P/E ratio of -0.62 and a beta of 2.62. Pain Therapeutics has a 1 year low of $0.81 and a 1 year high of $12.80.

In other Pain Therapeutics news, major shareholder Armistice Capital, Llc sold 1,200,000 shares of the stock in a transaction that occurred on Thursday, August 16th. The stock was sold at an average price of $1.02, for a total transaction of $1,224,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Armistice Capital Master Fund sold 512,660 shares of the stock in a transaction that occurred on Wednesday, October 3rd. The stock was sold at an average price of $1.31, for a total value of $671,584.60. The disclosure for this sale can be found here. Insiders sold 2,968,660 shares of company stock valued at $3,176,705 in the last three months. 31.40% of the stock is currently owned by company insiders.

About Pain Therapeutics

Pain Therapeutics, Inc develops drugs for nervous system disorders in the United States. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood-based diagnostic/biomarker to detect Alzheimer's disease.

See Also: How Important is Technical Analysis of Stocks

Earnings History for Pain Therapeutics (NASDAQ:PTIE)

Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply